Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives

by Roberto Mina, Stefania Oliva, Mario Boccadoro
Published 2020-07-01

Erratum: Mina, R.; et al. Minimal Residual Disease in Multiple Myeloma: State of the Art and Future Perspectives. <i>J. Clin. Med.</i> 2020, <i>9</i>, 2142

by Roberto Mina, Stefania Oliva, Mario Boccadoro
Published 2020-08-01

Managing visitors' flows in museums. The case of Firenze Card

by Stefania Oliva, Francesco Capone, Luciana Lazzeretti, Alessandra Petrucci
Published 2020-12-01

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma

by Stefania Oliva, Mattia D'Agostino, Mario Boccadoro, Alessandra Larocca
Published 2020-01-01

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

by Stefania Oliva, Rossella Troia, Mattia D'Agostino, Mario Boccadoro, Francesca Gay
Published 2018-11-01

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?

by Niccolo Bolli, Niccolo Bolli, Elisa Genuardi, Bachisio Ziccheddu, Bachisio Ziccheddu, Marina Martello, Stefania Oliva, Carolina Terragna
Published 2020-02-01

Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

by Stefania Oliva, Davine Hofste op Bruinink, Lucie Rihova, Mattia D’Agostino, Lucia Pantani, Andrea Capra, Bronno van der Holt, Rossella Troia, Maria Teresa Petrucci, Tania Villanova, Pavla Vsianska, Romana Jugooa, Claudia Brandt-Hagens, Milena Gilestro, Massimo Offidani, Rossella Ribolla, Monica Galli, Roman Hajek, Francesca Gay, Michele Cavo, Paola Omedé, Vincent H. J. van der Velden, Mario Boccadoro, Pieter Sonneveld
Published 2021-06-01